Going Long $MCKHello Everyone, We are setting a buy signal here on $MCK. We believe that it has formed a nice bottom and it has the potential to rally up to our price target at $162.96. For safety, we have set a Tight stop loss at $127.18. Best of Luck, Tashua Financialby Tashua_Financial9
McKesson after-hours guidance raiseAfter-hours today, McKesson raised its FY EPS guidance to 14.60-14.80, about 2% above the consensus analyst estimate of 14.41. Its last round of guidance was disappointing, so this reflects a significant improvement in the company's fundamentals. Even though the guidance bump was only 2%, it could catalyze a much larger move in the stock price, which was already trading at a low forward P/E of about 10. Today's guidance implies a forward P/E of more like 9.7 based on today's closing price. McKesson has been in an uptrend anyway, so fortunately for me, I already owned some shares.Longby ChristopherCarrollSmithUpdated 17
Mckesson weekly. I fucking hate everything about Mckessons software. The worst medical software on planet earth. Why do i say this? Because i am forced to use this train wreck.Longby Lucid_Liquidity6
MCK - DAILY CHARTHi, today we are going to talk about McKesson Corporation and its current landscape. The opioid crisis has been plaguing the U.S at the most for nearly two years now. With scary numbers like the record of 47,600* overdose deaths caused by opioids in 2017 but the number seems to start slowdown since 2018 were the war against opioids gained some traction. In the justice field, some companies have already faced some sort of rebuke for involvement and even a bit of responsibility for the opioid crisis. For example *Jun 2019, Insys Therapeutics Inc. had to file for bankruptcy after being convicted for conspiring to bribe doctors to increase opioid sales, ending up in a deal with the federal government of $225 million. * Aug 2019, Johnson & Johnson was obligated to pay $572 Million, as Oklahoma ruled that the company intentionally played down the dangers and oversold the benefits of opioids. * Oct 2019, Johnson & Johnson was once more condemned by two counties of Ohio to pay $20.4 million, with the accusation of having helped the opioid crisis to spread. Now, the drug distributor McKesson Corporation, is under investigation by the Federal Prosecutors in Brooklyn, into whether the company intentionally permitted that flood of opioids on the community. For now the U.S. Attorney’s Office in the Eastern District of New York it's just issuing subpoenas, but if they case sticks we might see what the murders of Julius Caesar saw, a pile of fire and anger from the people, so big that like Caesar butchers that were cast out of the city, the companies involved on this process can be drowned in liabilities and fines with the risk to be so badly damaged that may have the same fate of Insys Therapeutics Inc. The war against opioids it's just poised to grow up as every justice department across the country and every candidate that it's next to run on elections its eager to hang this trophy on the wall. *Source: Centers for Disease Control and Prevention (CDC) Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice. by Igor-Silva36
MCK - Earnings Miss, Channel IntactMCK had a poor earnings report on October 30th but despite the falling price it still managed to hold the ascending channel. The stock price is right at the gap resistance level but with the stock trying to escape an oversold condition it looks to have a lot more room to rise. I would be aiming for the resistance line of the ascending channel but $147.20 is the 61.8% Fibonacci Extension level which would be a good level to look for a pause in the rally.Longby ChartimisticUpdated 5
MCK Move up after failed breakdownThis accumulation pattern just below support and then push up through support and re-test could lead for some decent swing upside. Keep on watch.Longby UnknownUnicorn12362283
MCK Down assuming price breaks the drawn 50% retracement. Short term indicators confirm this (thus break of 50% level) NYSE:MCKby moglander04194
$MCK - Inverse Head & Shoulder Setup with daily TD 9 I'm very bullish on $MCK and their 2020 plan. The drug distribution company is selling off due to FDA issuing warnings to all distribution companies for shipping "illegitimate" opioid products. I encourage you all to look at the software side of $MCK's business and the McKesson 2020 plan. As for the charts, Daily TD 9 from Tone Vay's TD indicator + an inverse head and should forming. . . . . . . . . . . . . . . . . . . . . . P.S: America Will Never Be a Socialist Country. Longby BigDGoesHardUpdated 4
McKesson - $MCK Buy TargetsHere are a few buy targets for McKesson I will be looking at based on horizontal levels. Longby BigDGoesHardUpdated 3
Short-term opportunity on MCKShort-term trade on MCK. The 15m chart shows a clean 5-wave decline from 160 to 142.50, with nice alternation between Wave-2 and Wave-4. A 3-wave correction back into the 50% retracement level offers a good short opportunity. Initiating a short position with an immediate target at 142.50. A move above 157.50 invalidates the setup.Shortby UnknownUnicorn182749Updated 1
McKesson Corp (MCK) Intrinsic ValueRetorno de Capital (Greenblatt): 206.80% P/E (Greenblatt): 6 Margen de seguridad en base a descuento de flujo de Caja(Graham): 72%Longby Max_Pedregal1
MCK broken out of bearish channel set to slingshot One of the largest pharmaceutical drug distributors covering USA, Canada, Europe. Showing some bullish signs after coming off a 2 year downtrend, broken out of bearish channel, established priced floor at 135 and moving average cross over. relatively low PE ratio, beat earnings last 2 quarters with higher earnings projections moving forward according to analysts. Revenue and EPS growth seem to be picking up more as the company matures. Based off history if momentum picks up could see $300 price in 2 years.Longby Yogigolf1
Nice setup on MCK, longer termbreaking the downtrend. Should hit 200, then 240. Don't know much about it but like the chartLongby random.trader1
$MCK will it Rebound near 146.8 in the next few days? Gann Grid$MCK will it turn around near 146.8 in the next few days? Gann's GridLongby jayo8885
MCK - POTENTIAL BOTTOM Signal of a potential bottom from my dTFI on DAILY chart at horizontal support Longby Fiboman7
$MCK recovery play with breakout pendingnice looking chart...bullish if it can get over $152Longby Carr2
Short term upward momentum is intact.Monitor for a breakout above US$150.89. Target: US$157.65 & US$165.04. Support: US$150.83Longby LouiLow2
MCK(Daily). Head and Shoulders Top.(Retest)5 month Head and shoulders, Gapped Down on high Volume, 200 sma break and 2013 Trend_Line. Retest of Neck_Line.Shortby rv3
Stock that's being added to my watchlist *Weekly Breakout*Technicals -Price broke out to a new YTD High (+18.25% YTD vs. +7.06% SPX YTD) -Support between 230.50 - 232.70 -Resistance 244.00 -Weekly Chart did form doji at the highs so there is a chance of a retracement to support. Trade Idea Long at support upon receiving bullish confirmation. Recent 13F's Third Point LLC opened small new position. Pos. Size : 625,000 Shares valued at $141,000 (Options play) Analyst Price Targets Mizuho Reiterated Buy / Price Target Raised to $275 Deutsche Bank Reiterated Buy / Price Target Raised to $253 FBR Capital Reiterated Outperform / Price Target Raised to $250 Upcoming Corporate Events James Beer (Executive VP / CFO) will be presenting at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes at 8:00 AM PT on Tuesday, June 9, 2015.Longby Daniel.B225